TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07765160: A Phase I Clinical Trial Evaluating the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Characteristics of a Single Subcutaneous Administration of IBI3040 in Healthy Participants and Multiple Subcutaneous Admi

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 96 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07765160 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07765160 Rescue Dossier →